Regulatory Filings • Jul 8, 2013
Regulatory Filings
Open in ViewerOpens in native device viewer
PRESS RELEASE 8 July 2013
Lund, Sweden – 8 July 2013 - BioInvent International (OMXS:BINV) today announces that it will receive a milestone payment in connection with a partner's start of a phase I clinical study using a n-CoDeR® antibody.
BioInvent's pipeline of external drug programmes consists of another seven antibodies in pre-clinical development of which additional candidates are expected to enter clinical trials in 2013.
Cristina Glad, CEO of BioInvent, commented: "The advancement by one of our partners of an n-CoDeR® antibody into the clinic is an important step forward for BioInvent. Progress in our external drug programmes is a key driver for BioInvent's development."
-- END --
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.
The company's competitive position is underpinned by n-CoDeR® , a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibodybased drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.
Cristina Glad President and CEO +46 (0)46 286 85 51 +46 (0)708 16 85 70 [email protected]
The Trout Group Christine Yang Vice President Phone: +1 646 378 2929 E-mail: [email protected]
Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 [email protected] www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET on July 8, 2013.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.